GSK Stock Rises 2% as Japan Grants Orphan Status to Lung Cancer Drug
GSK shares closed up 2.07% at 1,977 pence in London after Japan granted orphan-drug status to its experimental lung cancer therapy risvutatug rezetecan. Chair Jonathan Symonds and director Gavin Screaton recently bought shares, and the company continued buybacks. GSK’s U.S.-listed shares rose about 1.7%. The stock remains 13.37% below its February high.